By: Adam Feuerstein | 04/10/14 - 10:24 AM EDT
You'd think I could get a few days off from writing about Northwest Biotherapeutics (NWBO), but no.
I'll keep this brief, but there's a couple of important points to be made about Northwest Bio's announcement of an "up to" $32 million financing.
1. Northwest Bio raised $15 million by selling stock at $6.60 per share, an 8% discount to Wednesday's closing price. The $32 million haul is aspirational and assumes the single investor in the deal later decides to buy the $17 million "non transferable oversubscription option."
2. Northwest Bio claims today's financing includes no warrants. Well, that's a bit of a fib. The "non transferable oversubscription option" is a warrant, even if you don't want to call it a warrant.
From today's press release:
The Stock Purchase Agreement also provides a non-transferable Oversubscription Option for the investor to purchase up to $17 million of common stock at $7.50 per share (approximately 5% premium to the closing market price) during the twelve months following the initial closing.My finance dictionary defines a warrant this way:
A warrant is a security that entitles the holder to buy the underlying stock of the issuing company at a fixed exercise price until the expiry date.
08/21/14 - 10:23 AM EDT
08/14/14 - 10:20 AM EDT
08/13/14 - 12:04 PM EDT
08/12/14 - 05:11 PM EDT
08/12/14 - 07:17 AM EDT
08/23/14 - 13:31 PM EDT
08/22/14 - 08:50 AM EDT
08/21/14 - 11:12 AM EDT
08/21/14 - 09:53 AM EDT
08/20/14 - 10:17 AM EDT
David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Access the tool that DOMINATES the Russell 2000 and the S&P 500.